Quantitative Perfusion-Weighted Magnetic Resonance Imaging in Uveal Melanoma

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2024 Sep 9

PMID 39250118

Authors

Lisa Klaassen

Myriam G Jaarsma-Coes

Marina Marinkovic

Gregorius P M Luyten

Coen R N Rasch

Teresa A Ferreira

Jan-Willem M Beenakker

Affiliations

Soon will be listed here.

Abstract

Purpose: Perfusion-weighted imaging (PWI; magnetic resonance imaging [MRI]) has been shown to provide valuable biological tumor information in uveal melanoma (UM). Clinically used semiquantitative methods do not account for tumor pigmentation and eye movement. We hypothesize that a quantitative PWI method that incorporates these, provides a more accurate description of tumor perfusion than the current clinical method. The aim of this study was to test this in patients with UM before and after radiotherapy.

Methods: Perfusion-weighted 3T MRIs were retrospectively analyzed in 47 patients with UM before and after radiotherapy. Tofts pharmacokinetic modeling was performed to determine vascular permeability (Ktrans), extracellular extravascular space (ve), and reflux rate (kep). These were compared with semiquantitative clinical parameters including peak intensity and outflow percentage.

Results: The effect of tumor pigmentation on peak intensity and outflow percentage was statistically significant (P < 0.01) and relative peak intensity was significantly different between melanotic and amelanotic tumors (1.5 vs. 1.9, P < 0.01). Before radiotherapy, median tumor Ktrans was 0.63 min-1 (range = 0.06-1.42 min-1), median ve was 0.23 (range = 0.09-0.63), and median kep was 2.3 min-1 (range = 0.6-5.0 min-1). After radiotherapy, 85% showed a decrease in Ktrans and kep (P < 0.01). Changes in tumor pigmentation before and after radiotherapy were small and not significant (median increase in T1 of 33 ms, P = 0.55).

Conclusions: Quantitative PWI parameters decreased significantly after radiotherapy and can therefore can serve as an early biomarker for treatment response assessment. However, due to the nonsignificant changes in tumor pigmentation before and after radiotherapy, the current semiquantitative method appears to be sufficiently sensitive for detection of changes in tumor perfusion.

References

Barboriak D, MacFall J, Viglianti B, Dewhirst Dvm M . Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging. 2008; 27(6):1388-98. PMC: 3755278. DOI: 10.1002/jmri.21344. View

Ferreira T, Jaarsma-Coes M, Marinkovic M, Verbist B, Verdijk R, Jager M . MR imaging characteristics of uveal melanoma with histopathological validation. Neuroradiology. 2021; 64(1):171-184. PMC: 8724164. DOI: 10.1007/s00234-021-02825-5. View

Jiang X, Asbach P, Willerding G, Dulce M, Xu K, Taupitz M . Dynamic contrast-enhanced MRI of ocular melanoma. Melanoma Res. 2015; 25(2):149-56. DOI: 10.1097/CMR.0000000000000142. View

Ma X, Lv K, Sheng J, Yu Y, Pang P, Xu M . Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer. Oncol Lett. 2019; 17(3):3077-3084. PMC: 6396180. DOI: 10.3892/ol.2019.9988. View

Wei W, Jia G, von Tengg-Kobligk H, Heverhagen J, Abdel-Rahman M, Wei L . Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. J Comput Assist Tomogr. 2017; 41(5):823-827. DOI: 10.1097/RCT.0000000000000598. View

Rodjan F, de Graaf P, van der Valk P, Moll A, Kuijer J, Knol D . Retinoblastoma: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. AJNR Am J Neuroradiol. 2012; 33(11):2129-35. PMC: 7965605. DOI: 10.3174/ajnr.A3119. View

Sharma A, Sharma S, Sood S, Seam R, Sharma M, Fotedar V . DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report. Pol J Radiol. 2019; 83:e220-e228. PMC: 6323583. DOI: 10.5114/pjr.2018.76271. View

Gelmi M, Wierenga A, Kroes W, van Duinen S, Karuntu J, Marinkovic M . Increased Histological Tumor Pigmentation in Uveal Melanoma Is Related to Eye Color and Loss of Chromosome 3/BAP1. Ophthalmol Sci. 2023; 3(3):100297. PMC: 10182323. DOI: 10.1016/j.xops.2023.100297. View

Parker G, Roberts C, MacDonald A, Buonaccorsi G, Cheung S, Buckley D . Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med. 2006; 56(5):993-1000. DOI: 10.1002/mrm.21066. View

10.

Khalifa F, Soliman A, El-Baz A, Abou El-Ghar M, El-Diasty T, Gimelfarb G . Models and methods for analyzing DCE-MRI: a review. Med Phys. 2014; 41(12):124301. DOI: 10.1118/1.4898202. View

11.

Jaarsma-Coes M, Ferreira T, Marinkovic M, Vu T, van Vught L, van Haren G . Comparison of Magnetic Resonance Imaging-Based and Conventional Measurements for Proton Beam Therapy of Uveal Melanoma. Ophthalmol Retina. 2022; 7(2):178-188. DOI: 10.1016/j.oret.2022.06.019. View

12.

Stalhammar G, Grossniklaus H . Intratumor Heterogeneity in Uveal Melanoma BAP-1 Expression. Cancers (Basel). 2021; 13(5). PMC: 7962103. DOI: 10.3390/cancers13051143. View

13.

Fleury E, Trnkova P, Spruijt K, Herault J, Lebbink F, Heufelder J . Characterization of the HollandPTC proton therapy beamline dedicated to uveal melanoma treatment and an interinstitutional comparison. Med Phys. 2021; 48(8):4506-4522. PMC: 8457201. DOI: 10.1002/mp.15024. View

14.

Tudorica L, Oh K, Roy N, Kettler M, Chen Y, Hemmingson S . A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings. Magn Reson Imaging. 2012; 30(9):1257-67. PMC: 3466402. DOI: 10.1016/j.mri.2012.04.009. View

15.

Klein S, Staring M, Murphy K, Viergever M, Pluim J . elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging. 2009; 29(1):196-205. DOI: 10.1109/TMI.2009.2035616. View

16.

Klaassen L, Jaarsma-Coes M, Verbist B, Vu T, Marinkovic M, Rasch C . Automatic Three-Dimensional Magnetic Resonance-based measurements of tumour prominence and basal diameter for treatment planning of uveal melanoma. Phys Imaging Radiat Oncol. 2022; 24:102-110. PMC: 9649381. DOI: 10.1016/j.phro.2022.11.001. View

17.

Tang M, Ferreira T, Marinkovic M, Jaarsma-Coes M, Klaassen L, Vu T . MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma. Neuroradiology. 2023; 65(8):1271-1285. PMC: 10227806. DOI: 10.1007/s00234-023-03166-1. View

18.

Fedorov A, Fluckiger J, Ayers G, Li X, Gupta S, Tempany C . A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation. Magn Reson Imaging. 2014; 32(4):321-9. PMC: 3965600. DOI: 10.1016/j.mri.2014.01.004. View

19.

Guo W, Zhang Y, Luo D, Yuan H . Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer. Br J Radiol. 2020; 93(1115):20200751. PMC: 8519657. DOI: 10.1259/bjr.20200751. View

20.

Jaarsma-Coes M, Klaassen L, Marinkovic M, Luyten G, Vu T, Ferreira T . Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients-A Systematic Review from an Ophthalmic Perspective. Cancers (Basel). 2023; 15(11). PMC: 10252038. DOI: 10.3390/cancers15112995. View